Can I read Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer on EtoBox?

Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer by Suresh Alati; Rajan Singh; Martin G. Pomper; Steven P. Rowe; Sangeeta Ray Banerjee is a Medicine article available to read on EtoBox.

What is Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer about?

Prostate cancer is a leading cause of cancer death in men worldwide. Among the various treatment options, radiopharmaceutical therapy has shown notable success in metastatic, castration-resistant disease. Radiopharmaceutical therapy is a systemic approach that delivers cytotoxic radiation doses precisely to the malignant tumors and/or tumor microenvironment. Therapeutic radiopharmaceuticals are composed of a therapeutic radionuclide and a high-affinity, tumor-targeting carrier molecule. Therapeutic radionuclides used in preclinical prostate cancer studies are primarily a-, b À -, or Auger-electron-emitting radiometals or radiohalogens. Monoclonal antibodies, antibody-derived fragments, peptides, and small molecules are frequently used as tumor-targeting molecules. Over the years, several important membrane-associated proteases and receptors have been identified, validated, and subsequently used for preclinical radiotherapeutic development for prostate cancer. Prostate-specific membrane antigen (PSMA) is the most well-studied prostate cancer-associated protease in preclinical literature. PSMA-targeting radiotherapeutic agents are being investigated using high-affinity antibody-and s

Who reads Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer?

Author

Suresh Alati; Rajan Singh; Martin G. Pomper; Steven P. Rowe; Sangeeta Ray Banerjee

Publisher

Elsevier BV

Published

2023

Language

EN

Field

Medicine (Health Sciences)